Drug intelligence / Profile preview

azaserine

Development stage
Discontinued
Lead developer
Streptomyces
Modality
Small Molecules
Administration
Intraperitoneal (experimental/animal Studies); Not Approved For Human Use
01

Overview

Azaserine is a **naturally occurring serine derivative diazo compound** with **antineoplastic** (anti-cancer), **antibiotic**, and **antifungal** properties. It acts primarily as a **purine antagonist** and as a **structural analogue of glutamine**, competitively inhibiting glutamine-dependent enzymatic activities—most notably **glutamine amidotransferase**, a key enzyme in purine biosynthesis and the metabolic hexosamine pathway. Azaserine **inhibits the rate-limiting step of the hexosamine biosynthesis pathway** and **irreversibly inhibits gamma-Glutamyltranspeptidase (GGT1)** by direct interaction at the substrate-binding pocket. It also dampens purine biosynthesis by reacting with cysteine residues in enzyme active sites, and induces DNA damage via formation of carboxymethylated bases and O6-methylguanine. It has been studied as a potential antineoplastic agent, but is not an approved or widely used pharmaceutical. Azaserine is isolated from Streptomyces species[1][2][3][5][8].

Other names
O-diazoacetyl-L-serine
02

Targets

GFAT1 (Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1)CHRM3 (M3)GGH (γ-glutamyl hydrolase)DNAGGT2P (Gamma-glutamyltransferase 1)

Beyond the preview

Go deeper on azaserine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on azaserine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call